News Category: Earnings News

– 3Q24 total revenues of $250.4 million , up 18% year-over-year – 3Q24 NUPLAZID ® (pimavanserin) net product sales of $159.2 million , up 10% year-over-year – 3Q24 DAYBUE ™ (trofinetide) net product sales of $91.2 million , up 36% year-over-year SAN DIEGO –(BUSINESS WIRE)–Nov.

– Second quarter total net product sales of $242.0 million , up 46% year-over-year SAN DIEGO –(BUSINESS WIRE)–Aug. 6, 2024– Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the second quarter ended June 30, 2024 . “In the second quarter of 2024, Acadia

– First quarter NUPLAZID ® (pimavanserin) net product sales of $129.9 million – First quarter DAYBUE ™ (trofinetide) net product sales of $75.9 million SAN DIEGO –(BUSINESS WIRE)–May 8, 2024– Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the first quarter

– Study Did Not Meet Primary Endpoint SAN DIEGO –(BUSINESS WIRE)–Mar. 11, 2024– Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced top-line results from the Phase 3 ADVANCE-2 trial evaluating pimavanserin for the treatment of negative symptoms of schizophrenia.

– 2023 total net product sales of $726.4 million , reflecting 40% revenue growth. – Fourth quarter DAYBUE ™ (trofinetide) net product sales of $87.1 million and full year 2023 net product sales of $177.2 million . – Fourth quarter NUPLAZID ® (pimavanserin) net product sales of $143.9 million and

– Company reports record revenues resulting from strong DAYBUE launch and growth in NUPLAZID franchise – 3Q23 DAYBUE ™ (trofinetide) net product sales of $66.9 million   – 3Q23 NUPLAZID ® (pimavanserin) net product sales of $144.8 million   SAN DIEGO –(BUSINESS WIRE)–Nov.

– 2Q23 DAYBUE ™ (trofinetide) net product sales of $23.2 million – 2Q23 NUPLAZID ® (pimavanserin) net product sales of $142.0 million – Expanded licensing agreement for trofinetide includes ex-North American rights SAN DIEGO –(BUSINESS WIRE)–Aug. 2, 2023– Acadia Pharmaceuticals Inc.

– 1Q23 NUPLAZID ® net sales of $118.5 million – Announced the U.S. FDA Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome in Adult and Pediatric Patients Two Years of Age and Older on March 10, 2023 – Announced DAYBUE Availability on April 17, 2023 SAN DIEGO –(BUSINESS WIRE)–May

– Full year 2022 net sales of $517.2 million , an increase of 7% over 2021 – Prescription Drug User Fee Act (PDUFA) action date set for March 12, 2023 , for trofinetide for the treatment of Rett syndrome SAN DIEGO –(BUSINESS WIRE)–Feb. 27, 2023– Acadia Pharmaceuticals Inc.

– 3Q22 net sales of $130.7 million – Prescription Drug User Fee Act action date set for March 12, 2023   for trofinetide for the treatment of Rett syndrome SAN DIEGO –(BUSINESS WIRE)–Nov. 2, 2022– Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the third